MetfOrmin BenefIts Lower Extremities With Intermittent Claudication

Intermittent Claudication Clinical Trial

— MOBILE IC  

Official title:

Metformin BenefIts Lower Extremities With Intermittent Claudication (MOBILE_IC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05132439
• Other study ID #: CARB-012-20F
• Secondary ID: I01CX002150
• Status: Recruiting
• Phase: Phase 3
• Start date: March 1, 2022
• Est. completion date: February 28, 2031

Study information

• Verified date: October 2023
• Source: VA Office of Research and Development
• Contact: Edith I Tzeng, MD
• Phone: (412) 360-1657
• Email: Edith.Tzeng[@]va.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Peripheral arterial disease (PAD) affects over 20% of aged adults and is very common among Veterans due significant tobacco use. PAD is due to the progressive blockage of peripheral arteries, predominantly to the legs, and results in intermittent claudication (IC) or recurrent muscle pain with activity secondary to insufficient blood supply. Those with PAD and IC experience a progressive decline in walking and poor quality of life. There is no effective medical treatment for PAD and IC. Metformin is a safe and effective treatment for Type 2 diabetes but it can also reduce inflammation, oxidative stress, and improve energy requirements as well as improve blood flow to the legs. Therefore, the investigators will test the ability of Metformin to improve overall functional status, reduce PAD progression, and reduce systemic inflammation in Veterans suffering from PAD and IC in a randomized, placebo controlled trial: Metformin BenefIts Lower Extremities with Intermittent Claudication (MOBILE IC) Trial. The success of this trial may identify a safe and effective treatment for PAD and IC.

Description:

This is a quadruple blinded randomized controlled trial. Therefore, the allocation of participants to either placebo or metformin is unknown by the participant, research personnel, investigator, or blinded statistician. A total of 200 participants will be randomized over the course of 3 years. Study drug is administered to participants after all inclusion and no exclusion criteria is confirmed, informed consent is completed, and they are randomized. Study drug is continued throughout for 6 months following randomization. Participants are prospectively observed and monitored for 12 months after randomization. The patients' involvement (study visits/study phone calls) will last 12 months. Then, for 5 years, the study team will do a medical chart review as outlined in the ICF and protocol. All main study endpoints are within the 12-month time point. Secondary endpoints including MACE and MALE - major adverse cardiac and major adverse limb events - are time to event end points which can continue beyond the 12-month study time frame and will inform not only the effect of metformin on IC but also the natural history of IC among patients enrolled in the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: February 28, 2031
• Est. primary completion date: February 28, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 89 Years

Eligibility

Inclusion Criteria:

• Male and Female Veteran >35 & <89

• Symptoms of Intermittent claudication

• Medically stable, optimal medical therapy (for >3 months prior to randomization which includes - statin and anti-platelet therapy, blood pressure control, smoking cessation and physical activity counseling)

a. Participants may not comply with the above measures to meet inclusion criteria, but investigator driven attempts to maximize the optimal medical therapy, as tolerated, for each participant prior to trial enrollment

• PAD as defined by ABI <0.9 or >0.9 with evidence of PAD as documented by pulse volume recordings (within 6 months prior to expected randomization date)

• Maximum Walking Distance (MWD) on the 6-minute walk test (6MWT) of greater than or equal to 50 meters with onset of pain before or at 400 meters without the use of a walker (cane is acceptable; within 6 months of expected randomization date)

Exclusion Criteria:

• Diabetes (Type I or II) or Hemoglobin A1c>6.5 (within 6 months of expected randomization)

• Currently Taking metformin or have previously taken metformin (within 6 months of enrollment)

• Medical condition that limit their ability to ambulate other than PAD (i.e., Angina, CHF, pulmonary disease requiring oxygen, malignancy requiring treatment, etc.)

• Prior above or below knee amputation

• Critical limb threatening ischemia (i.e., non-healing wounds or rest pain)

• Planned hospital admission, major operation, or lower extremity revascularization to be completed (within 12 months after expected randomization date)

• Prior major operation or lower extremity revascularization (within the 3 months before expected randomization)

• Unable to complete quality of life testing due to Non-English Speaking and/or Dementia

• Kidney disease - dialysis or eGFR<45 (within 6 months of expected randomization date)*

• Planned iodinated contrasted study (within 6 months of expected randomization date)

• Evidence current or history of hepatic failure

• Women who are pregnant or breast feeding

• Unable to swallow uncrushed pills

• Investigator expects inclusion could cause harm to subject

Related Conditions & MeSH terms

• Intermittent Claudication

Intervention

Drug:
• Metformin ER
Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties
• placebo
Matched to active study drug

Locations

Country	Name	City	State
United States	VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA	Pittsburgh	Pennsylvania

Sponsors (4)

Lead Sponsor	Collaborator
VA Office of Research and Development	Northwestern University, San Francisco Veterans Affairs Medical Center, University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximal Walking distance on the 6 minute walk test	This validated measure of functional status in PAD and IC is highly reproducible and the ideal measure of real-life walking capacity	6 month
Secondary	6 minute walk test	This validated measure of functional status in PAD and IC is highly reproducible and the ideal measure of real-life walking capacity. The six minute walk test includes maximal walking distance, pain free walking distance, time to pain onset.	6 month
Secondary	6 minute walk test	This validated measure of functional status in PAD and IC is highly reproducible and the ideal measure of real-life walking capacity. The six minute walk test includes maximal walking distance, pain free walking distance, time to pain onset.	12 month
Secondary	Cardiopulmonary exercise test	The CPET is a well validated, reproducible measure symptom-limited (maximal) aerobic and anaerobic capacity in patients with PAD and IC and correlates with systemic disease severity and outcome	6 month
Secondary	Cardiopulmonary exercise test	The CPET is a well validated, reproducible measure symptom-limited (maximal) aerobic and anaerobic capacity in patients with PAD and IC and correlates with systemic disease severity and outcome	12 month
Secondary	EndoPAT	Systemic endothelial cell function and health will be evaluated by EndoPAT, measuring peripheral artery tonometry and generates reproducible digital pulse wave amplitude before and during reactive hyperemia induced by brachial artery occlusion with a blood pressure cuff	6 month
Secondary	Grip Strength	Grip strength with a dynamometer provides a digital reading of force	6 month
Secondary	EndoPAT	Systemic endothelial cell function and health will be evaluated by EndoPAT, measuring peripheral artery tonometry and generates reproducible digital pulse wave amplitude before and during reactive hyperemia induced by brachial artery occlusion with a blood pressure cuff	12 month
Secondary	Grip Strength	Grip strength with a dynamometer provides a digital reading of force	12 month
Secondary	Ankle brachial index and pulse volume recording	The ABI and PVR assess regional lower extremity blood supply in large-vessels and contribution of collaterals	6 month
Secondary	Ankle brachial index	The ABI assesses regional lower extremity blood supply in large-vessels and contribution of collaterals	12 month
Secondary	Health related quality of life questionnaire	Functionality outcomes will be supported by the general (SF-36) and disease specific (Vascular Quality of Life Questionnaire [VascQol6]) health related quality of life questionnaires.	6 month
Secondary	Health related quality of life questionnaires	Functionality outcomes will be supported by the general (SF-36) and disease specific (Vascular Quality of Life Questionnaire [VascQol6]) health related quality of life questionnaires.	12 month
Secondary	Walking Impairment Questionnaire	A subjective measure of patient-reported walking performance developed for PAD	6 month
Secondary	Walking Impairment Questionnaire	A subjective measure of patient-reported walking performance developed for PAD	12 month
Secondary	Freedom from major cardiac and major limb events	Major cardiac events include: composite of CVD mortality, myocardial ischemia, coronary revascularization, hospitalization for heart failure, non-fatal stroke, and transient ischemic attack. Major adverse limb events include: composite of minor and major amputations, revascularization	12 month